A history of SARS CoV - older than you might think...

On May 3rd 2023, Dr David Martin introduced the proccedings at the 3rd EU Covid-19 Summit in Brussels, giving a history of the research into coronavirus as an infectious pathogen that could be modified.

Here's the timeline, with some key quotes from Dr Martin:

1965

Coronavirus, as a model of a pathogen, was isolated and identified as one of the first infectious, replicatable viral models that could be used to modify a series of other experiences of the human condition. It was immediately identified as a pathogen that could be used and modified for a whole host of reasons.

1966

The very first CoV coronavirus model was used as a transatlantic biological experiment in human manipulation, with data sharing between the US and the UK.

1967

The first human trials on inoculating people with modified coronavirus.

1975-7

Started figuring out how to modify coronavirus by putting it into different animals – pigs & dogs.

1990

Realised coronavirus as an infectious agent was an industrial problem for two primary industries: dogs and pigs. It created gastrointestinal problems for the animals and that became the basis for Pfizer’s first spike protein vaccine patent, filed that year.

They also found out that coronavirus vaccines didn’t work because the virus mutates. From 1990 until 2018, every single publication - and there are thousands - concluded that the coronavirus escapes the vaccine impulse because it modifies and mutates too quickly for vaccines to be effective.

(They knew for 30 years before Covid-19 that coronavirus vaccines don’t and cannot work.)

2002

University of North Carolina at Chapel Hill patented “an infectious, replication defective” clone of coronavirus. Funded by Fauci. SARS was engineered – it’s the weaponisation of the common cold.

2003

CDC filed the patent on coronavirus isolated from humans. The application was rejected twice (because you cannot patent something that exists in nature) until the CDC bribed the patent office.

2005

The SARS pathogen was specifically labelled as a “bioterrorism and bioweapon platform technology”. It’s a biowarfare enabling agent – that’s been the official classification since 2005.

“That feels like not public health. That feels like not medicine. That feels like a weapon designed to take out humanity, that’s what it feels like. And it feels like that because that’s exactly what it is.”

2014

The university of North Carolina, Chapel Hill, was given an exemption by NIAID from the moratorium on gain of function research using coronavirus in vivo, because their grants had already been funded!

“A biological weapons lab facility received an exemption from the gain of function moratorium, so that by 2016 we could publish the journal article that said, ‘SARS coronavirus is poised for human emergence.”

2015

In March, at a workshop at the National Academy of Sciences (NAS) in Washington, convened by the Institute of Medicine, Peter Daszak, president of EcoHealth Alliance, said:

“Until an infectious disease crisis is very real, present and at the emergency threshold, it is often largely ignored. To sustain the funding base beyond the crisis we need to increase the public understanding for the need for medical countermeasures, such as a pan-influenza or pan-coronavirus vaccine. A key driver is the media, and the economics will follow the hype. We need to use that hype to our advantage, to get to the real issues. Investors will respond if they see profit at the end of the process.”

2016

The SARS-like virus ‘poised for human emergence’ was named WIV1-CoV – Wuhan Institute of Virology Virus 1 – at the proceedings of the National Academy of Sciences.

In describing the published research paper, ‘SARS-like WIV1-CoV poised for human emergence’, it says:

“This manuscript describes efforts to extend surveillance beyond sequence analysis, constructing chimeric and full-length zoonotic coronaviruses to evaluate emergence potential. Focusing on SARS-like virus sequences isolated from Chinese horseshoe bats, the results indicate a significant threat posed by WIV1-CoV. Both full-length and chimeric WIV1-CoV readily replicated efficiently in human airway cultures and in vivo, suggesting capability of direct transmission to humans. In addition, while monoclonal antibody treatments prove effective, the SARS-based vaccine approach failed to confer protection.”

2017-18

A phrase entered into common parlance among the community: “There is going to be an accidental or intentional release of a respiratory pathogen”.

2019

In April 2019 – 7 months before the allegation of ‘patient 1’ – four Moderna vaccine patents were modified to include the term ‘accidental or intentional release of a respiratory pathogen’.

“The intent was to get the world to accept a universal vaccine template, and the intent was to use coronavirus to get there.”

---

See PDF of patents timeline with links to the patents.

Also see Dr Martin's similar testimony, given to the Investigative Corona Committee Germany two years ago in my blog: 'We made SARS, and we patented it on April 19th 2002'.